Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

N
Nabil Adra, MD

Primary Investigator

S
Sandeep Batra, MD

Primary Investigator

Overview

The purpose of this study is to determine if accelerated BEP will be more effective but not significantly more toxic than standard BEP.

Description

The purpose of this study is to determine if accelerated BEP (Bleomycin, Etoposide, cisPlatin) is superior to standard BEP as first-line chemotherapy for intermediate and poor-risk metastatic GCTs.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Germ Cell Tumor
  • Age: Between 11 Years - 45 Years
  • Gender: All

Inclusion Criteria

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Age greater than/equal to 11 years and less than or equal to 45 years on the date of randomisation
  • Histologically or cytologically confirmed germ cell tumour (non-seminoma or seminoma); or exceptionally raised tumour markers (AFP greater than/equal to 1000ng/mL and/or HCG greater than/equal to 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 09 Mar 2024. Study ID: 1902750740 (1808832730) (PHO-COG-AGCT1532)

Connect with a study center near you

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center